BACKGROUND: We set out to define the characteristics of humoral autoimmunity against ZnT8 in children and adolescents with newly diagnosed T1D in relation to age and metabolic status at diagnosis, human leucocyte antigen (HLA) genotype and family history of T1D. METHODS: A total of 2115 subjects <15 years of age were analysed for antibodies against zinc transporter 8, ICA, GADA, IAA, IA-2A, HLA DR-DQ genotype, blood pH, plasma glucose and β-hydroxybutyrate concentrations. Their family history of T1D was also recorded. RESULTS: Zinc transporter 8 antibodies (ZnT8A) were detected in 63% of the cases. ZnT8A positivity was associated with older age at diagnosis (mean 8.2 years versus 7.5 years, p < 0.001). Seven subjects (0.3%) had ZnT8A as their single autoantibody. Diabetic ketoacidosis at diagnosis was less common among subjects with ZnT8A than among those without (16% versus 20%, p = 0.012). The prevalence of ZnT8A was decreased in DR3/DR4 heterozygotes when compared with those with other DR combinations (p < 0.001). Subjects with the neutral DR13-DQB1*0604 haplotype tested more frequently positive for ZnT8A than the rest of the population (p < 0.001). A positive family history of T1D showed no association with ZnT8A prevalence or levels. CONCLUSIONS: Antibodies for ZnT8 is related to age and metabolic status at diagnosis as well as HLA genotype but does not significantly improve the detection rate of β-cell autoimmunity in Finnish children and adolescents affected by T1D.
BACKGROUND: We set out to define the characteristics of humoral autoimmunity against ZnT8 in children and adolescents with newly diagnosed T1D in relation to age and metabolic status at diagnosis, human leucocyte antigen (HLA) genotype and family history of T1D. METHODS: A total of 2115 subjects <15 years of age were analysed for antibodies against zinc transporter 8, ICA, GADA, IAA, IA-2A, HLA DR-DQ genotype, blood pH, plasma glucose and β-hydroxybutyrate concentrations. Their family history of T1D was also recorded. RESULTS:Zinc transporter 8 antibodies (ZnT8A) were detected in 63% of the cases. ZnT8A positivity was associated with older age at diagnosis (mean 8.2 years versus 7.5 years, p < 0.001). Seven subjects (0.3%) had ZnT8A as their single autoantibody. Diabetic ketoacidosis at diagnosis was less common among subjects with ZnT8A than among those without (16% versus 20%, p = 0.012). The prevalence of ZnT8A was decreased in DR3/DR4 heterozygotes when compared with those with other DR combinations (p < 0.001). Subjects with the neutral DR13-DQB1*0604 haplotype tested more frequently positive for ZnT8A than the rest of the population (p < 0.001). A positive family history of T1D showed no association with ZnT8A prevalence or levels. CONCLUSIONS: Antibodies for ZnT8 is related to age and metabolic status at diagnosis as well as HLA genotype but does not significantly improve the detection rate of β-cell autoimmunity in Finnish children and adolescents affected by T1D.
Authors: Matilda Juusola; Anna Parkkola; Taina Härkönen; Heli Siljander; Jorma Ilonen; Hans K Åkerblom; Mikael Knip Journal: Diabetes Care Date: 2015-10-30 Impact factor: 19.112
Authors: Martina Fabris; Silvia Zago; Marco Liguori; Maria Teresa Trevisan; Manuela Zanatta; Alberto Comici; Giorgio Zanette; Eva Carlin; Francesco Curcio; Elio Tonutti Journal: Auto Immun Highlights Date: 2015-07-21
Authors: Karla Fabiana Brasil Gomes; Cintia Semzezem; Rodolfo Batista; Rosa Tsuneshiro Fukui; Aritania Sousa Santos; Márcia Regina Correia; Maria Rita Passos-Bueno; Maria Elizabeth Rossi da Silva Journal: Sci Rep Date: 2017-03-16 Impact factor: 4.379
Authors: Vibha Anand; Ying Li; Bin Liu; Mohamed Ghalwash; Eileen Koski; Kenney Ng; Jessica L Dunne; Josefine Jönsson; Christiane Winkler; Mikael Knip; Jorma Toppari; Jorma Ilonen; Michael B Killian; Brigitte I Frohnert; Markus Lundgren; Anette-Gabriele Ziegler; William Hagopian; Riitta Veijola; Marian Rewers Journal: Diabetes Care Date: 2021-06-23 Impact factor: 17.152
Authors: Stavroula A Paschou; Nektaria Papadopoulou-Marketou; George P Chrousos; Christina Kanaka-Gantenbein Journal: Endocr Connect Date: 2017-11-30 Impact factor: 3.335